Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells ; volume:12 ; number:1 ; day:22 ; month:9 ; year:2012 ; pages:1-11 ; date:12.2012
BMC cancer ; 12, Heft 1 (22.9.2012), 1-11, 12.2012
- Creator
-
Papa, Anne-Laure
- Contributor
-
Basu, Sudipta
Sengupta, Poulomi
Banerjee, Deboshri
Sengupta, Shiladitya
Harfouche, Rania
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-419
- URN
-
urn:nbn:de:1111-201603042857
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Papa, Anne-Laure
- Basu, Sudipta
- Sengupta, Poulomi
- Banerjee, Deboshri
- Sengupta, Shiladitya
- Harfouche, Rania
- SpringerLink (Online service)
Other Objects (12)
Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
Gemcitabine-loaded chitosan nanoparticles enhanced apoptotic and ferroptotic response of gemcitabine treatment alone in the pancreatic cancer cells in vitro
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
Gemcitabine-loaded chitosan nanoparticles enhanced apoptotic and ferroptotic response of gemcitabine treatment alone in the pancreatic cancer cells in vitro
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
Gemcitabine-loaded chitosan nanoparticles enhanced apoptotic and ferroptotic response of gemcitabine treatment alone in the pancreatic cancer cells in vitro
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)